Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 13,638 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer, Breast Neoplasm
Interventions: Docetaxel - Dose A, Anastrozole, cyclophosphamide, Docetaxel - Dose B, Doxorubicin hydrochloride, Tamoxifen Citrate, Capecitabine - Dose B, Capecitabine - Dose A; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 50
States / cities: Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more

Conditions: Onychomycosis
Interventions: NAB001, Vehicle alone; Drug
Lead sponsor: Promius Pharma, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 22
States / cities: Phoenix, Arkansas • Encino, California • San Diego, California + 19 more

Conditions: Alopecia, Baldness
Interventions: bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer
Interventions: E75 + GM-CSF vaccine; Biological
Lead sponsor: COL George Peoples, MD, FACS; Federal
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Windber, Pennsylvania

Conditions: Psoriasis
Interventions: BMS-986165, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 101
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 77 more

Conditions: Hair Diseases, Alopecia, Hair Thinning
Interventions: Scalp tattoo, Canfield HairMetrix®, TargetCool, Microneedle-facilitated lidocaine application; Device
Lead sponsor: Recens Medical, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hidradenitis Suppurativa
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Vitiligo
Interventions: Etanercept; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Breast Cancer
Interventions: Cisplatin, carboplatin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more

Conditions: Melanoma, Metastatic Kidney Cancer
Interventions: Interleukin-2 (IL-2); Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Beaumont, California • Loma Linda, California

Conditions: Psoriatic Arthritis
Interventions: AbGn-168H; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Palo Alto, California • Sarasota, Florida + 4 more

Conditions: Breast Cancer, Obesity, Overweight
Interventions: Calorie restricted diet plus exercise, Weight management classes; Other
Lead sponsor: USDA Grand Forks Human Nutrition Research Center; Federal
Eligibility: 44 Years to 75 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: questionnaire administration, quality-of-life assessment, management of therapy complications, exercise intervention; Other · Procedure · Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Onychomycosis
Interventions: MOB015B; Drug
Lead sponsor: Moberg Pharma AB; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Metastatic Melanoma
Interventions: Tremelimumab, MEDI3617; Drug
Lead sponsor: F. Stephen Hodi, MD; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions: Triamcinolone Acetonide, Oleogel-S10; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more

Conditions: Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Interventions: Colchicine, Dapsone, Azathioprine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 12
States / cities: Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 9 more

Conditions: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
Interventions: IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E); Drug
Lead sponsor: Immuneering Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 20
States / cities: Scottsdale, Arizona • Duarte, California • San Diego, California + 16 more

Conditions: Breast Cancer
Interventions: TAD; Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Parapsoriasis
Interventions: Bexarotene 1% gel; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sunburn
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Urticaria Pigmentosa, Cutaneous Mastocytosis
Interventions: skin biopsy, blood draw; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 3 Months to 23 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

The Ohio State University Dermatology Biorepository

Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

Weight Loss Pilot Study in Postmenopausal Breast Cancer Survivors

Exercise Program for Early Breast Cancer Survivors

A Study of the Systemic Absorption of MOB015B

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

A Randomized Multicenter Study for Isolated Skin Vasculitis

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases

Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis

Hats on Head Start: A A Survey of Sun Protection Behaviors in Head Start and Other Early Childhood Education Programs

Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations